Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Merck KGaA Company

MRK.DE
DE0006599905
659990

Price

156.95
Today +/-
+1.80
Today %
+1.15 %
P

Merck KGaA stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Merck KGaA stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Merck KGaA stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Merck KGaA stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Merck KGaA's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Merck KGaA Stock Price History

DateMerck KGaA Price
10/11/2024156.95 undefined
10/10/2024155.15 undefined
10/9/2024155.60 undefined
10/8/2024154.50 undefined
10/7/2024152.90 undefined
10/4/2024154.90 undefined
10/3/2024156.65 undefined
10/2/2024157.40 undefined
10/1/2024156.40 undefined
9/30/2024158.00 undefined
9/27/2024160.55 undefined
9/26/2024160.00 undefined
9/25/2024155.05 undefined
9/24/2024156.00 undefined
9/23/2024155.55 undefined
9/20/2024157.55 undefined
9/19/2024166.85 undefined
9/18/2024166.00 undefined
9/17/2024166.65 undefined
9/16/2024166.05 undefined
9/13/2024168.20 undefined

Merck KGaA Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Merck KGaA, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Merck KGaA from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Merck KGaA’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Merck KGaA. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Merck KGaA’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Merck KGaA’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Merck KGaA’s growth potential.

Merck KGaA Revenue, EBIT and net profit per share

DateMerck KGaA RevenueMerck KGaA EBITMerck KGaA Net Income
2029e26.03 B undefined0 undefined1.67 B undefined
2028e26.29 B undefined6.3 B undefined1.6 B undefined
2027e25.4 B undefined5.83 B undefined1.48 B undefined
2026e23.95 B undefined5.63 B undefined1.42 B undefined
2025e22.79 B undefined5.14 B undefined1.31 B undefined
2024e21.6 B undefined4.15 B undefined1.15 B undefined
202320.99 B undefined4.22 B undefined2.82 B undefined
202222.23 B undefined5.26 B undefined3.33 B undefined
202119.69 B undefined4.36 B undefined3.06 B undefined
202017.53 B undefined3.07 B undefined1.99 B undefined
201916.15 B undefined2.51 B undefined1.32 B undefined
201814.84 B undefined2.13 B undefined3.37 B undefined
201714.52 B undefined2.4 B undefined2.61 B undefined
201615.02 B undefined2.49 B undefined1.63 B undefined
201512.84 B undefined2.24 B undefined1.11 B undefined
201411.36 B undefined1.84 B undefined1.16 B undefined
201311.1 B undefined2.14 B undefined1.2 B undefined
201211.17 B undefined1.89 B undefined567 M undefined
201110.28 B undefined1.42 B undefined618 M undefined
20109.29 B undefined1.4 B undefined632 M undefined
20097.75 B undefined870 M undefined366 M undefined
20087.56 B undefined1.19 B undefined367 M undefined
20077.06 B undefined1.24 B undefined3.5 B undefined
20066.28 B undefined1.11 B undefined983 M undefined
20055.97 B undefined882 M undefined659 M undefined
20045.47 B undefined748 M undefined659 M undefined

Merck KGaA Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
3.213.564.084.155.356.97.77.577.345.475.976.287.067.567.759.2910.2811.1711.111.3612.8415.0214.5214.8416.1517.5319.6922.2320.9921.622.7923.9525.426.2926.03
-10.9214.681.7728.8728.9711.63-1.65-3.01-25.459.015.3112.307.102.5019.9310.608.73-0.702.4113.0416.97-3.372.208.878.5612.2812.93-5.572.895.505.096.073.52-1.00
58.0757.5056.7356.3054.4651.6752.1749.8751.3658.9160.3061.5874.7874.7873.8174.3272.8771.7473.0368.9768.2765.3865.0763.9963.1661.3262.7962.1660.13------
1.862.042.312.342.913.564.023.783.773.233.63.875.285.655.726.917.498.028.17.848.779.829.459.4910.210.7512.3613.8212.62000000
0.450.430.660.520.610.730.870.590.720.750.881.111.241.190.871.41.421.892.141.842.242.492.42.132.513.074.365.264.223.935.085.515.836.30
14.1312.1016.2112.5611.3710.6111.247.829.8113.6614.7817.6017.5915.7111.2315.1013.8216.9219.2516.1617.4716.5916.5314.3415.5317.5122.1723.6420.1118.2022.2823.0122.9623.94-
0.180.250.370.320.210.250.630.20.210.660.660.983.50.370.370.630.620.571.21.161.111.632.613.371.321.993.063.332.821.151.311.421.481.61.67
-37.5750.20-14.44-33.7516.51154.66-67.732.46216.83-49.17256.05-89.51-0.2772.68-2.22-8.25111.99-3.74-3.7246.2359.9129.52-60.8850.5353.758.87-15.09-59.2113.728.634.227.754.51
-----------------------------------
-----------------------------------
265349349349349349349349368386388388432435435435435435435434.78434.78434.78434.78434.79434.21434.79434.57434.78434.78000000
-----------------------------------
Details

Keystats

Revenue and Growth

The Merck KGaA Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Merck KGaA is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                         
0.550.4610.380.470.50.470.350.310.391.490.610.872.0512.062.313.355.041.020.980.622.20.61.231.691.722.08
0.590.680.770.741.191.191.181.211.140.991.181.281.411.661.792.32.332.122.022.222.742.892.923.283.643.393.854.244.11
000067798255698072119164174478173465251463546719784460589520492446473
0.720.790.850.821.171.211.271.191.171.021.121.221.161.411.371.671.691.531.471.662.612.612.632.763.343.293.94.634.64
0.210.260.360.380.540.40.260.310.260.160.160.150.150.260.160.220.150.20.290.980.430.470.490.540.830.841.051.161.1
2.072.192.972.333.383.33.263.152.942.624.033.313.834.365.535.676.46.637.3810.367.347.677.469.2499.2810.9812.212.39
1.361.471.531.581.891.972.152.132.021.861.861.782.282.442.613.243.112.952.652.994.014.234.514.816.216.427.228.29.06
0.290.340.410.640.630.790.640.20.20.120.071.640.130.10.120.140.060.080.060.080.110.190.42000000
000000000036000000211719.1201541614746830922947971
0.130.190.210.21.882.050.110.120.10.110.151.068.176.275.667.97.056.255.285.710.939.988.327.249.187.657.617.346.55
0.050.430.640.76001.921.721.540.840.84001.931.944.584.724.74.585.6914.4915.0213.5813.7617.1415.961718.3917.85
0000.060.090.130.170.190.180.170.30.30.530.540.860.860.791.020.851.041.181.161.31.231.531.651.621.461.68
1.832.442.793.244.494.9554.364.043.13.254.7911.111.2911.1816.7215.7215.0213.4315.5330.7430.5928.1727.6534.8132.5234.3836.3336.1
3.894.635.765.577.868.258.267.516.985.727.288.114.9215.6516.7122.3922.1221.6520.8225.8938.0838.2635.6236.8943.8141.845.3648.5448.5
                                                         
440440440440442442447447492495497497565565565565565565565565.2565565565565565565565565565
0.811.011.31.251.311.311.851.571.842.362.783.268.068.948.98.488.670003.813.813.813.813.813.813.813.810
00000.220.340000000001.281.218.559.3410.317.038.059.912.5313.2414.5620.4922.6824.63
000000000000000001.241.110.861.381.56-0.280.290.25-1.990.292.681.48
00000000000000000000000000000
1.251.451.741.691.982.12.32.012.332.853.283.758.639.519.4610.3310.4510.3611.0211.7412.7913.991417.217.8716.9525.1529.7426.68
0.270.30.350.320.540.480.530.510.470.370.710.610.650.840.941.21.11.291.361.541.922.052.21.772.051.772.382.52.55
00000000.060.070.060.2500000.470.450.550.510.440.540.60.780.80.790.981.21.411.17
0.250.280.230.260.490.640.90.650.380.320.560.971.631.271.181.361.481.671.62.552.912.682.93.754.474.194.354.414.36
00.070.160.220.320.270.390.060.420.020.010.290.0100.50.041.010.7501.451.271.860.840.110.210.2000
00.821.281.032.392.422.261.030.670.080.270.20.290.270.210.290.330.310.430.592.741.911.932.094.332.12.51.20.63
0.521.462.031.833.743.814.072.312.010.851.82.072.572.382.823.364.364.563.96.579.389.098.648.5211.849.2310.439.518.7
1.220.610.760.710.530.630.121.360.790.220.650.611.051.081.65.134.153.243.213.449.518.717.956.618.599.758.279.29.24
0.020.030.040.060.090.090.140.130.10.050.040.040.820.90.761.381.321.190.670.822.932.721.491.291.831.441.411.291.13
0.851.061.171.251.451.551.591.671.721.721.461.571.81.732.012.151.82.241.983.353.43.693.483.243.644.363.832.532.67
2.091.691.982.032.062.271.853.152.611.982.152.233.663.74.388.667.276.675.857.6115.8415.1212.9211.1414.0615.5513.5113.0213.04
2.623.1643.855.816.085.925.464.622.833.954.36.246.087.212.0211.6311.239.7514.1725.2324.2121.5619.6625.924.7823.9522.5321.74
3.874.615.745.547.788.178.227.476.955.687.238.0514.8615.5916.6622.3522.0821.5920.7725.9238.0138.235.5636.8643.7641.7349.152.2748.42
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Merck KGaA provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Merck KGaA's financial health and stability.

Assets

Merck KGaA's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Merck KGaA must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Merck KGaA after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Merck KGaA's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.190.260.380.330.220.260.660.220.220.670.6713.520.380.380.640.630.581.211.161.121.632.623.41.321.993.073.342.83
0.170.20.270.260.320.440.410.430.470.380.290.30.921.2211.261.61.41.461.361.511.931.761.811.941.941.762.031.88
00000000000000000000000000000
-83-74-111-140-280155-33-18573-199-91-220-522-491-15365-347142-235512-644-569-1,427-466-561-396-273-1,083-896
24-163-976-255-466-33-8-362-138-271-2,703-78144-181-608354-206-332204-488-250-2,523149-5962-27-34
00000000000000761342383032480000000000
1051370000000000002603173575614910000000000
0.280.390.380.360.270.60.560.420.750.490.730.811.221.021.371.781.272.472.232.712.22.512.72.222.863.484.624.263.78
-396-405-347-372-405-471-523-411-306-255-299-309-403-535-563-500-446-473-516-624-693-848-1,311-1,016-1,021-1,563-1,421-1,806-2,023
-0.61-0.74-0.32-0.55-1.36-0.280.10.02-0.311.31-0.2-1.46-2.73-0.08-2.16-3.88-0.9-1.16-0.87-1.64-11.94-0.5-1.152.19-6.15-1.34-1.58-2.74-1.89
-0.21-0.340.02-0.17-0.950.190.630.43-01.570.1-1.15-2.320.45-1.6-3.38-0.45-0.68-0.36-1.02-11.240.350.163.21-5.130.22-0.16-0.940.13
00000000000000000000000000000
-0.070.270.62-0.241.19-0.06-0.51-0.28-0.69-1.550.650.080.07-0.210.922.880.03-1.1-0.651.627.73-1.31-1.25-2.062.59-0.84-1.75-0.59-0.57
1.090000000000000000000000000000
0.750.250.46-0.421.14-0.21-0.71-0.52-0.46-1.720.44-0.21.49-0.670.642.54-0.38-1.52-1.070.767.16-1.91-1.87-2.831.9-1.52-2.5-1.56-1.73
-0.28-0.02-0.16-0.180.10-0.15-0.190.28-0.12-0.16-0.231.5-0.24-0.18-0.26-0.33-0.32-0.31-0.74-0.44-0.46-0.47-0.61-0.53-0.52-0.58-0.73-0.88
0000-151-158-50-49-53-44-57-49-77-212-104-86-86-102-109-122-129-136-155-162-162-168-181-239-284
0.42-0.090.54-0.610.050.11-0.04-0.12-0.040.071-0.86-0.030.27-0.150.4-0.01-0.210.251.9-2.050.11-0.351.58-1.390.580.54-0.050.13
-115.9-15.430.4-17.6-14012739.910.2446230.6433.2501.9814.4488.4807.41,282.2825.21,998.91,708.92,081.31,502.21,6621,3851,2031,8351,9143,1952,4531,761
00000000000000000000000000000

Merck KGaA stock margins

The Merck KGaA margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merck KGaA. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merck KGaA.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Merck KGaA's sales revenue. A higher gross margin percentage indicates that the Merck KGaA retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Merck KGaA's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Merck KGaA's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Merck KGaA's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Merck KGaA. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Merck KGaA's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Merck KGaA Margin History

Merck KGaA Gross marginMerck KGaA Profit marginMerck KGaA EBIT marginMerck KGaA Profit margin
2029e60.13 %0 %6.42 %
2028e60.13 %23.94 %6.08 %
2027e60.13 %22.96 %5.84 %
2026e60.13 %23.51 %5.95 %
2025e60.13 %22.57 %5.75 %
2024e60.13 %19.19 %5.34 %
202360.13 %20.11 %13.45 %
202262.16 %23.64 %14.96 %
202162.79 %22.17 %15.52 %
202061.32 %17.51 %11.33 %
201963.16 %15.53 %8.17 %
201863.99 %14.34 %22.74 %
201765.07 %16.53 %17.94 %
201665.38 %16.59 %10.84 %
201568.26 %17.47 %8.68 %
201468.97 %16.16 %10.18 %
201373.03 %19.25 %10.83 %
201271.74 %16.92 %5.07 %
201172.87 %13.82 %6.01 %
201074.32 %15.1 %6.8 %
200973.81 %11.23 %4.72 %
200874.78 %15.71 %4.86 %
200774.78 %17.59 %49.6 %
200661.58 %17.6 %15.64 %
200560.3 %14.78 %11.04 %
200458.91 %13.66 %12.04 %

Merck KGaA Stock Sales Revenue, EBIT, Earnings per Share

The Merck KGaA earnings per share therefore indicates how much revenue Merck KGaA has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Merck KGaA earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Merck KGaA's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Merck KGaA’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Merck KGaA's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Merck KGaA Revenue, EBIT and net profit per share

DateMerck KGaA Sales per ShareMerck KGaA EBIT per shareMerck KGaA Earnings per Share
2029e201.41 undefined0 undefined12.92 undefined
2028e203.45 undefined0 undefined12.37 undefined
2027e196.53 undefined0 undefined11.48 undefined
2026e185.29 undefined0 undefined11.02 undefined
2025e176.31 undefined0 undefined10.14 undefined
2024e167.13 undefined0 undefined8.92 undefined
202348.28 undefined9.71 undefined6.5 undefined
202251.13 undefined12.09 undefined7.65 undefined
202145.3 undefined10.04 undefined7.03 undefined
202040.33 undefined7.06 undefined4.57 undefined
201937.2 undefined5.78 undefined3.04 undefined
201834.12 undefined4.89 undefined7.76 undefined
201733.39 undefined5.52 undefined5.99 undefined
201634.56 undefined5.73 undefined3.75 undefined
201529.54 undefined5.16 undefined2.56 undefined
201426.13 undefined4.22 undefined2.66 undefined
201325.51 undefined4.91 undefined2.76 undefined
201225.69 undefined4.34 undefined1.3 undefined
201123.62 undefined3.26 undefined1.42 undefined
201021.36 undefined3.23 undefined1.45 undefined
200917.81 undefined2 undefined0.84 undefined
200817.37 undefined2.73 undefined0.84 undefined
200716.34 undefined2.87 undefined8.1 undefined
200616.2 undefined2.85 undefined2.53 undefined
200515.38 undefined2.27 undefined1.7 undefined
200414.18 undefined1.94 undefined1.71 undefined

Merck KGaA business model

Merck is one of the oldest and most well-known companies in the pharmaceutical and chemical industry. It was founded as a pharmacy in Darmstadt in 1668 and has since developed into a global company that is successful worldwide. Merck's business model is based on various business areas, all of which are based on scientific research and innovation. The three main business areas are the Life Science, Healthcare, and Performance Materials divisions, all of which focus on providing products and services for a wide range of industries. Life Science is Merck's largest business area, focusing on providing materials, products, instruments, and services for scientific research and biopharmaceutical production. The company offers a wide range of products that focus on the work of researchers and scientists in molecular biology, cell technology, and genomics. Healthcare is another important business area for Merck, focusing on the manufacture and marketing of innovative drugs and treatments for patients. The company offers products for the treatment of diseases such as cancer, multiple sclerosis, and schizophrenia. Performance Materials is Merck's third business area, specializing in the production of materials and technologies for various industries such as the automotive industry, electronics, and packaging. The company focuses on the development of innovative materials such as liquid crystals and organic photovoltaic materials. Merck is also known for its research and development, and the company invests significant resources in developing new products and technologies. This is also evident in the extensive portfolio of products offered by Merck. The company offers a wide range of products ranging from laboratory and analysis equipment to pharmaceuticals and biopharmaceuticals to specialty chemicals. An example of an important product from Merck is the rheumatoid arthritis drug Remicade, which was developed in collaboration with Johnson & Johnson. Merck is also one of the leading manufacturers of liquid crystals for use in displays and electronic devices. Merck is a company committed to social responsibility and sustainability. The company is involved in many areas, including environmental, social, and governance issues. Merck is committed to developing sustainable products and technologies and is dedicated to promoting education, health, and social justice in the communities where it operates. Overall, Merck is a leading company in the pharmaceutical and chemical industry, known for its innovation, research and development, as well as its social responsibility and sustainability. With currently approximately 58,000 employees and annual sales of 17.4 billion euros, the global company network is represented in 67 countries and demonstrates the quality and capabilities of the company worldwide. Merck KGaA is one of the most popular companies on Eulerpool.com.

Merck KGaA revenue by segment

In the annual report of the Merck KGaA share (DE0006599905, 659990, MRK.DE), it breaks down its revenues into 3 segments: 1. Life Science, 2. Healthcare, 3. Performance Materials. The Merck KGaA stock (WKN: 659990, ISIN: DE0006599905, Ticker Symbol: MRK.DE) is a leading investment for investors interested in participating in the Health Care sector.

  • 42 % Life Science

  • 42 % Healthcare

  • 16 % Performance Materials

Merck KGaA SWOT Analysis

Strengths

Merck has several key strengths that contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong brand reputation and recognition globally
  • Extensive research and development capabilities
  • Diverse product portfolio with a focus on innovative healthcare solutions
  • Well-established distribution channels and strong relationships with healthcare providers
  • Robust financial performance and solid profitability

Weaknesses

Despite its strengths, Merck also faces certain weaknesses that may hinder its growth and competitiveness within the market. These weaknesses include:

  • Dependency on a limited number of blockbuster drugs for a significant portion of its revenue
  • Relatively high research and development costs compared to competitors
  • Vulnerability to the impact of patent expirations and generic competition
  • Challenges in adapting to rapidly evolving healthcare regulations and policies

Opportunities

There are several opportunities that Merck can capitalize on to drive future growth and success. These opportunities include:

  • Increasing demand for personalized medicine and targeted therapies
  • Expanding presence in emerging markets with rising healthcare spending
  • Exploring strategic partnerships and collaborations to enhance research and development efforts
  • Investing in digital healthcare technologies to improve patient outcomes and healthcare delivery

Threats

Merck faces several threats that could potentially impact its market position and profitability. These threats include:

  • Intense competition from other pharmaceutical companies
  • Regulatory challenges and potential litigation risks
  • Uncertainty surrounding healthcare policies and reimbursement systems
  • Increase in counterfeit drugs and intellectual property infringements

Merck KGaA Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Merck KGaA historical P/E ratio, EBIT multiple, and P/S ratio

Merck KGaA shares outstanding

The number of shares was Merck KGaA in 2023 — This indicates how many shares 434.778 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Merck KGaA earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Merck KGaA's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Merck KGaA’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Merck KGaA's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Merck KGaA stock splits

In Merck KGaA's history, there have been no stock splits.

Merck KGaA dividend history and estimates

In 2023, Merck KGaA paid a dividend amounting to 2.2 EUR. Dividend means that Merck KGaA distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Merck KGaA provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Merck KGaA’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Merck KGaA's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Merck KGaA Dividend History

DateMerck KGaA Dividend
2029e2.42 undefined
2028e2.42 undefined
2027e2.42 undefined
2026e2.42 undefined
2025e2.42 undefined
2024e2.42 undefined
20232.2 undefined
20221.85 undefined
20211.4 undefined
20201.3 undefined
20191.25 undefined
20181.25 undefined
20171.2 undefined
20161.05 undefined
20151 undefined
20140.95 undefined
20130.85 undefined
20120.75 undefined
20110.63 undefined
20100.5 undefined
20090.75 undefined
20081 undefined
20070.08 undefined
20060.42 undefined
20050.4 undefined
20040.39 undefined

Merck KGaA dividend payout ratio

In 2023, Merck KGaA had a payout ratio of 24.18%. The payout ratio indicates the percentage of the company's profits that Merck KGaA distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Merck KGaA represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Merck KGaA could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Merck KGaA's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Merck KGaA Payout Ratio History

DateMerck KGaA Payout ratio
2029e23.47 %
2028e23.53 %
2027e23.34 %
2026e23.55 %
2025e23.71 %
2024e22.76 %
202324.18 %
202224.18 %
202119.91 %
202028.45 %
201941.25 %
201816.11 %
201720.03 %
201628.02 %
201539.2 %
201435.69 %
201330.69 %
201257.69 %
201144.01 %
201034.48 %
200989.29 %
2008119.05 %
20070.93 %
200616.54 %
200523.53 %
200423.03 %
Unfortunately, there are currently no price targets and forecasts available for Merck KGaA.

Merck KGaA latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20241.99 2.2  (10.63 %)2024 Q2
3/31/20241.89 2.06  (9.07 %)2024 Q1
12/31/20231.93 1.85  (-4.23 %)2023 Q4
9/30/20232.01 2.07  (2.88 %)2023 Q3
6/30/20232.21 2.2  (-0.56 %)2023 Q2
3/31/20232.4 2.36  (-1.83 %)2023 Q1
12/31/20222.48 2.32  (-6.41 %)2022 Q4
9/30/20222.67 2.68  (0.52 %)2022 Q3
6/30/20222.57 2.64  (2.92 %)2022 Q2
3/31/20222.4 2.41  (0.62 %)2022 Q1
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Merck KGaA stock

Eulerpool World ESG Rating (EESG©)

90/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

71

Environment

Scope 1 - Direct Emissions
1,425,000
Scope 2 - Indirect emissions from purchased energy
242,000
Scope 3 - Indirect emissions within the value chain
6,616,000
Total CO₂ emissions
1,667,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees43
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Merck KGaA shareholders

%
Name
Stocks
Change
Date
7.36742 % BlackRock Institutional Trust Company, N.A.9,521,800-91,16012/8/2023
5.05792 % MFS Investment Management6,536,95508/9/2023
3.01926 % Fidelity Management & Research Company LLC3,902,15008/9/2023
2.98569 % Amundi Asset Management, SAS3,858,766-26,02012/13/2023
2.95013 % The Vanguard Group, Inc.3,812,8116,3473/31/2024
2.94555 % DWS Investment GmbH3,806,89408/9/2023
1.82270 % Norges Bank Investment Management (NBIM)2,355,688-676,91012/31/2023
1.39235 % Deka Investment GmbH1,799,506-8,2603/31/2024
1.32040 % Union Investment Privatfonds GmbH1,706,508144,82812/31/2023
1.30916 % BlackRock Advisors (UK) Limited1,691,9919,5183/31/2024
1
2
3
4
5
...
10

Merck KGaA Executives and Management Board

Ms. Belen Garijo62
Merck KGaA Chairman of the Executive Board, Chief Executive Officer
Compensation 10.53 M
Dr. Kai Beckmann57
Merck KGaA Member of the Executive Board, Chief Executive Officer - Electronics
Compensation 8.25 M
Mr. Marcus Kuhnert54
Merck KGaA Member of the Executive Board, Chief Financial Officer
Compensation 7.56 M
Mr. Peter Guenter61
Merck KGaA Member of the Executive Board, Chief Executive Officer - Healthcare
Compensation 5.59 M
Mr. Matthias Heinzel56
Merck KGaA Member of the Executive Board, Chief Executive Officer - Life Science
Compensation 5.23 M
1
2
3
4
...
5

Most common questions regarding Merck KGaA

What values and corporate philosophy does Merck KGaA represent?

Merck represents a strong commitment to its core values and corporate philosophy. With over a century of experience, the company prioritizes innovation, integrity, and excellence. By focusing on scientific advancements, Merck strives to make a positive impact on global healthcare. Its dedication to ethical business practices ensures transparency, trust, and accountability. Merck emphasizes collaboration and teamwork, fostering a culture that encourages diverse perspectives and inclusivity. As a leading pharmaceutical company, Merck continually seeks to improve the well-being of individuals and communities worldwide through its mission of advancing science and healthcare.

In which countries and regions is Merck KGaA primarily present?

Merck is primarily present in various countries and regions worldwide. The company has a strong global presence and operates in multiple key markets. Some of the primary regions where Merck operates include North America, Europe, Asia-Pacific, Latin America, and the Middle East. Merck's diverse international presence enables it to serve a wide range of customers and expand its reach in both developed and emerging markets.

What significant milestones has the company Merck KGaA achieved?

Merck, a global pharmaceutical company, has achieved several significant milestones throughout its history. One notable achievement is the discovery of groundbreaking medicines and vaccines in various therapeutic areas. Additionally, Merck has garnered accolades for its research and development efforts, advancing medical science and improving patient outcomes. The company has also played a crucial role in public health initiatives, such as developing treatments for HIV/AIDS and providing affordable access to essential medications. With a commitment to innovation and scientific excellence, Merck continues to make strides in addressing unmet medical needs and improving global healthcare.

What is the history and background of the company Merck KGaA?

Merck, a global pharmaceutical company, has a rich history and background. Established in 1668, Merck has been dedicated to improving human health for over 350 years. With its headquarters in Darmstadt, Germany, the company has evolved into a leading scientific research and development organization, focusing on innovative medicines, vaccines, and healthcare solutions. Merck has a strong global presence, operating in more than 140 countries. Over the years, it has expanded its portfolio to address a wide range of diseases and conditions, including cancer, infectious diseases, cardiovascular disorders, and more. Merck remains committed to innovation, scientific excellence, and improving the lives of patients worldwide.

Who are the main competitors of Merck KGaA in the market?

The main competitors of Merck in the market include pharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, and GlaxoSmithKline. These companies operate in the same industry and offer similar products and services, competing for market share and innovation. Although each company has its own unique strengths and areas of focus, Merck faces intense competition in the global pharmaceutical market from these key players.

In which industries is Merck KGaA primarily active?

Merck is primarily active in the pharmaceutical and life sciences industries. As a global healthcare company, Merck focuses on discovering, developing, manufacturing, and marketing innovative medicines, vaccines, and animal health products. With a strong emphasis on research and development, Merck operates in various therapeutic areas such as oncology, immunology, cardiovascular diseases, infectious diseases, and neurology. The company's commitment to advancing healthcare solutions and improving patient outcomes has made it a leader in the industry. Merck's portfolio encompasses a wide range of prescription drugs, over-the-counter products, and biologic therapies, serving millions of people worldwide.

What is the business model of Merck KGaA?

The business model of Merck is centered around the development, manufacturing, and sale of pharmaceutical, healthcare, and life science products. As a leading global healthcare company, Merck focuses on research and innovation to provide innovative and high-quality solutions for patients and healthcare professionals. Through its diverse portfolio of prescription medicines, vaccines, biologic therapies, and animal health products, Merck aims to improve health outcomes worldwide. With a strong emphasis on scientific advancements and a commitment to delivering value, Merck strives to address unmet medical needs and contribute to the well-being of individuals and communities across the globe.

What is the P/E ratio of Merck KGaA 2024?

The Merck KGaA P/E ratio is 59.19.

What is the P/S ratio of Merck KGaA 2024?

The Merck KGaA P/S ratio is 3.16.

What is the Quality Investing of Merck KGaA?

The Quality Investing for Merck KGaA is 7/10.

What is the revenue of Merck KGaA 2024?

The expected Merck KGaA revenue is 21.6 B EUR.

How high is the profit of Merck KGaA 2024?

The expected Merck KGaA profit is 1.15 B EUR.

What is the business model of Merck KGaA

The Merck Group is a global company active in various sectors of the chemical, pharmaceutical, and biotechnology industries. The company's strategy is based on three pillars: innovation, expertise, and internationality. The pharmaceutical sector of the company specializes in the development, production, and marketing of prescription drugs. Merck offers both patented medications and innovative biological treatment options in this area. These include medications for cancer, multiple sclerosis, as well as a variety of pain relievers and anti-inflammatory drugs. In addition to the development of prescription drugs, Merck also has a division for the production of over-the-counter medications and dietary supplements. Another important division of Merck is the Life Science division. This includes the development and production of laboratory technologies, biopharmaceuticals, and research instruments. This includes, for example, cell culture systems or high-tech laboratory equipment for protein expression analysis. Merck's Life Science division is a leader in biotechnology and offers research solutions for industry and science. Furthermore, Merck is also active in the Performance Materials business unit. Here, the company produces, among other things, liquid crystals, organic light-emitting diodes (OLEDs), or high-tech materials for the semiconductor industry. Merck's Performance Materials division is considered the world's leading provider of high-tech materials. Another pillar of Merck is its Consumer Health products. This includes the production and marketing of over-the-counter medications for self-medication, which are available in pharmacies and drugstores. These include, for example, pain relievers, cough and cold remedies, or dietary supplements. Merck's Consumer Health products are distributed worldwide and have a high level of awareness. Merck's business model is designed for long-term success and stable growth. Innovation and collaboration with experts and partners are of great importance. Merck focuses on strong international orientation and the exploration of new markets. The company also engages with society and advocates for sustainable development. In summary, Merck offers innovative and high-quality products and services in the areas of pharmaceuticals, Life Science, Performance Materials, and Consumer Health. The company's expertise lies in the development of new technologies and biotechnological processes. The goal of the company is to serve existing markets but also to explore new ones in order to achieve long-term growth.

What is the Merck KGaA dividend?

Merck KGaA pays a dividend of 1.85 EUR distributed over 1 payouts per year.

How often does Merck KGaA pay dividends?

Merck KGaA pays out a dividend 1 times a year.

What is the Merck KGaA ISIN?

The ISIN of Merck KGaA is DE0006599905.

What is the Merck KGaA WKN?

The WKN of Merck KGaA is 659990.

What is the Merck KGaA ticker?

The ticker of Merck KGaA is MRK.DE.

How much dividend does Merck KGaA pay?

Over the past 12 months, Merck KGaA paid a dividend of 2.2 EUR . This corresponds to a dividend yield of about 1.4 %. For the coming 12 months, Merck KGaA is expected to pay a dividend of 2.42 EUR.

What is the dividend yield of Merck KGaA?

The current dividend yield of Merck KGaA is 1.4 %.

When does Merck KGaA pay dividends?

Merck KGaA pays a quarterly dividend. This is distributed in the months of May, May, June, May.

How secure is the dividend of Merck KGaA?

Merck KGaA paid dividends every year for the past 26 years.

What is the dividend of Merck KGaA?

For the upcoming 12 months, dividends amounting to 2.42 EUR are expected. This corresponds to a dividend yield of 1.54 %.

In which sector is Merck KGaA located?

Merck KGaA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Merck KGaA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Merck KGaA from 5/2/2024 amounting to 2.2 EUR, you needed to have the stock in your portfolio before the ex-date on 4/29/2024.

When did Merck KGaA pay the last dividend?

The last dividend was paid out on 5/2/2024.

What was the dividend of Merck KGaA in the year 2023?

In the year 2023, Merck KGaA distributed 1.85 EUR as dividends.

In which currency does Merck KGaA pay out the dividend?

The dividends of Merck KGaA are distributed in EUR.

All fundamentals about Merck KGaA

Our stock analysis for Merck KGaA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merck KGaA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.